Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
The European Medicines Agency ((EMA)) has detected a rare newside effectcalled capillary leak syndrome following the vaccination with the COVID-19 vaccine developed by...
German Scientist Discovers What Causes Rare Blood Clots In Some AstraZeneca Jab RecipientsA German scientist may have found a solution to one of the biggest problems plaguing the...
"They Didn't Even Try To Respect The Contract" - EU Demands Massive Fine In Lawsuit Against AstraZenecaAfter suing AstraZeneca for falling far short of its promise to deliver...
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Sell | Neutral | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 436.95 | 436.95 | 432.60 | +0.80 | +0.18% | 14.06M | London | |||
| 329.90 | 332.60 | 321.80 | +7.10 | +2.20% | 3.59M | London | |||
| 191.80 | 195.90 | 188.75 | -3.35 | -1.72% | 25.71M | London | |||
| 1,403.40 | 1,408.00 | 1,399.60 | +6.80 | +0.49% | 5.58M | London | |||
| 129.84 | 130.50 | 128.12 | +0.04 | +0.03% | 52.95M | London | |||
| 86.84 | 90.76 | 85.70 | -1.50 | -1.70% | 7.63M | London | |||
| 259.00 | 259.00 | 250.00 | +38.00 | +17.35% | 5.57M | London | |||
| 60.25 | 61.35 | 60.20 | +0.25 | +0.42% | 229.03K | London | |||
| 436.00 | 438.00 | 422.50 | +3.00 | +0.69% | 887.12K | London | |||
| 76.00 | 79.00 | 76.00 | +0.10 | +0.13% | 1.94M | London | |||
| 203.20 | 203.70 | 199.48 | +2.80 | +1.40% | 26.68M | London | |||
| 20.15 | 20.45 | 20.15 | -0.35 | -1.71% | 5.92K | London | |||
| 6,119.00 | 6,154.00 | 6,090.00 | +86.0 | +1.43% | 1.67M | London | |||
| 601.00 | 607.50 | 587.00 | +2.50 | +0.42% | 1.15M | London | |||
| 1,894.00 | 1,930.50 | 1,893.00 | -4.50 | -0.24% | 234.05K | London |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
